|Bid||1.4400 x 2900|
|Ask||1.4500 x 1000|
|Day's Range||1.4300 - 1.5400|
|52 Week Range||0.5800 - 5.0600|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 21, 2022 - Feb 25, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Shares of the cancer drugmaker Clovis Oncology (NASDAQ: CLVS) are under pressure yet again today. After this latest dip, Clovis' stock is down by over 46% for the year. The biotech released its 2022 second-quarter earnings report ahead of the opening bell Monday morning, and its latest financial results aren't a hit with shareholders.
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.
Clovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?